465 related articles for article (PubMed ID: 20159940)
41. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
Kuo MT; Fu S; Savaraj N; Chen HH
Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.
Ip V; Liu JJ; McKeage MJ
Clin Exp Pharmacol Physiol; 2013 Jun; 40(6):371-8. PubMed ID: 23556474
[TBL] [Abstract][Full Text] [Related]
43. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
44. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
45. The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex.
Ma G; Wu Q; Wu X; Arnesano F; Natile G; Sletten E; Liu Y
J Inorg Biochem; 2015 Dec; 153():239-246. PubMed ID: 26235215
[TBL] [Abstract][Full Text] [Related]
46. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
47. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.
Liu JJ; Jamieson SM; Subramaniam J; Ip V; Jong NN; Mercer JF; McKeage MJ
Cancer Chemother Pharmacol; 2009 Sep; 64(4):847-56. PubMed ID: 19466412
[TBL] [Abstract][Full Text] [Related]
48. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
[TBL] [Abstract][Full Text] [Related]
49. [Structure-functional organization of eukaryotic high-affinity copper importer CTR1 determines its ability to transport copper, silver and cisplatin].
Skvortsov AN; Zatulovskiĭ EA; Puchkova LV
Mol Biol (Mosk); 2012; 46(2):335-47. PubMed ID: 22670529
[TBL] [Abstract][Full Text] [Related]
50. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.
Ip V; Liu JJ; Mercer JF; McKeage MJ
Mol Pain; 2010 Sep; 6():53. PubMed ID: 20836889
[TBL] [Abstract][Full Text] [Related]
52. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
53. Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Huq F
J Ovarian Res; 2013 Nov; 6(1):78. PubMed ID: 24209693
[TBL] [Abstract][Full Text] [Related]
54. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
55. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
56. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
Bompiani KM; Tsai CY; Achatz FP; Liebig JK; Howell SB
Metallomics; 2016 Sep; 8(9):951-62. PubMed ID: 27157188
[TBL] [Abstract][Full Text] [Related]
57. Overcoming platinum drug resistance with copper-lowering agents.
Chen HH; Kuo MT
Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
[TBL] [Abstract][Full Text] [Related]
58. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
59. Role of the copper transporter, CTR1, in platinum-induced ototoxicity.
More SS; Akil O; Ianculescu AG; Geier EG; Lustig LR; Giacomini KM
J Neurosci; 2010 Jul; 30(28):9500-9. PubMed ID: 20631178
[TBL] [Abstract][Full Text] [Related]
60. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
